Candriam SCA
FTH icon

Candriam SCA’s Faeth Therapeutics FTH Stock Holding History

Candriam SCA’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.5M Buy
+319,663
New +$10M 0.04% 286

Other funds holding FTH

RIS
Richmond Investment Services Mequon, Wisconsin $316M AUM 19.72% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
Financial Consulate
Financial Consulate Hunt Valley, Maryland $899M AUM 14.82% 1-Year Est. Return
Physician Wealth Advisors
Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Candriam SCA's FTH Position: Q3 2026 in Review

Candriam SCA opened a new position in Faeth Therapeutics (FTH) in Q3 2026: 319,663 shares worth $9.5M. The stake represents 0.04% of the portfolio and ranks #286 among its holdings.

9 funds tracked by Wall St. Rank hold FTH as of Q3 2026.

  • Candriam SCA held 319,663 shares of Faeth Therapeutics worth $9.5M as of Q3 2026.
  • Faeth Therapeutics was a new Candriam SCA position in Q3 2026.
  • Faeth Therapeutics made up 0.04% of Candriam SCA's portfolio in Q3 2026, its #286 holding.
  • 9 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2026.

Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.